Of 1100 women whose primary and/or metastatic breast cancers have been analyzed for estrophilin, 30% are receptor-rich and 70% receptor-poor. On the basis of 134 treated patients, nearly two-thirds of the receptor-rich group can expect objective benefit from endocrine therapy, whereas few if any of the receptor-poor patients will respond. Thus, estrophilin… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.